Miconazole + Polymyxin B + Prednisolone

Verify with FDA CVM →

803 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
803
Total Reports
10
Deaths Reported
120.0%
Death Rate

Active Ingredients

MiconazolePolymyxin BPrednisolone

Administration Routes

Auricular (Otic)UnknownTopicalOralIntraocularOtherOphthalmicIntra-Articular

Species Affected

Dog 719
Unknown 55
Cat 25
Human 4

Most Affected Breeds

Retriever - Labrador 67
Unknown 60
Terrier - Yorkshire 46
Dog (unknown) 45
Chihuahua 42
Pug 31
Retriever - Golden 28
Crossbred Canine/dog 26
Maltese 26
Shih Tzu 24

Most Reported Reactions

Loss of hearing 193
Deafness 155
Lack of efficacy - NOS 100
Impaired hearing 79
Hearing decreased 67
Vomiting 38
Behavioural disorder NOS 38
Ear discharge 36
Partial deafness 31
Ear infection NOS 30
Drug administration duration too long 29
Deafness NOS 28

Outcome Breakdown

Ongoing
333 (44.6%)
Outcome Unknown
262 (35.1%)
Recovered/Normal
94 (12.6%)
Recovered with Sequela
48 (6.4%)
Euthanized
6 (0.8%)
Died
4 (0.5%)

Data Summary

Metric Value
Total adverse event reports 803
Reports involving death 10
Case-fatality rate (reported events) 120.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Miconazole + Polymyxin B + Prednisolone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 803 adverse event reports referencing Miconazole + Polymyxin B + Prednisolone, including 10 reports in which the animal died — a 120.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Miconazole, Polymyxin B, Prednisolone. Reported administration routes include Auricular (Otic), Unknown, Topical, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Miconazole + Polymyxin B + Prednisolone reports are Dog (719 reports), Unknown (55 reports), Cat (25 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (67), Unknown (60), Terrier - Yorkshire (46) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Miconazole + Polymyxin B + Prednisolone are Loss of hearing (193), Deafness (155), Lack of efficacy - NOS (100), Impaired hearing (79). Of the 747 reports with a coded outcome, Ongoing is the leading category at 44.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Miconazole + Polymyxin B + Prednisolone.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial